Biopharma PEG Scientific Inc.

07/15/2025

🚀 New on our blog
Bristol Myers Squibb disclosed the structure of BMS-986238, a second-generation macrocyclic PD-L1 inhibitor.

This novel candidate showcases how strategic molecular engineering—powered by PEG technology—can unlock oral potential in peptide drugs.

🔍 Key features of BMS-986238:

• C18 fatty acid chain boosts albumin binding → significantly longer half-life
• PEG linker acts as a flexible spacer → maintains PD-L1 binding, adds solubility
• Optimized design enables both weekly subcutaneous injection and daily oral dosing

🧪 The molecule recently completed Phase 1 (NCT0668458), demonstrating strong systemic exposure and PD-L1 affinity—without relying on traditional antibodies.

At Biopharma PEG, we’re proud to support the innovation behind such molecules with:
✔️ Monodispersed and Polydispersed GMP-grade PEGs
✔️ Custom PEG linkers tailored to peptide and small molecule drug delivery
✔️ Scalable supply from mg to 100 kg

💡 Whether you're extending half-life or improving oral bioavailability, our PEG solutions help drive the next wave of therapeutic breakthroughs.

📎 Learn more: https://www.biochempeg.com/article/441.html
📩 Contact: sales@biochempeg.com

07/08/2025

🚀 Featured PEGs at Biopharma PEG!

Looking for high-purity monodispersed or polydispersed PEGs for your next project?

Whether you need grams for R&D or 100+ kilograms for GMP production, we've got your supply chain covered.

🔬 Explore our full PEG lineup: https://www.biochempeg.com/
📧 Contact us: sales@biochempeg.com

06/24/2025

HER3-DXd is out—but HER3-targeted cancer therapy is moving forward.

At ASCO 2025:
✅ Zenocutuzumab approved for NRG1+ NSCLC
✅ BL-B01D1 shows 69.2% ORR in tough NSCLC cases
✅ DB-1310 shows promise in EGFR-mutant NSCLC

The future may belong to bispecifics and ADC combos.

Patritumab deruxtecan (HER3-DXd) withdrawal marks a setback in NSCLC. Learn about successful HER3 strategies like Zenocutuzumab and promising bispecific ADCs.

06/13/2025

🎉 Big News from Biopharma PEG!
We’re thrilled to announce that our self-developed Hydrazide-PEG-Hydrazide (HZ-PEG-HZ, 1K) has officially received Drug Master File (DMF) approval from the U.S. FDA!
📄 DMF No.: 041864

This achievement reflects our strong R&D capabilities and unwavering commitment to delivering high-purity, GMP-grade PEG derivatives that meet the rigorous demands of global pharmaceutical development.
📌 GMP-grade available
📌 Scalable supply from milligrams to 100 kilograms
With this regulatory milestone, Biopharma PEG remains a trusted partner for companies developing advanced biologics, ADCs, and targeted drug delivery systems.
🔗 Learn more: https://www.biochempeg.com/article/438.html

06/11/2025

🔬 PROTAC Degraders in Clinical Trials: 2025 Update
PROTACs (Proteolysis Targeting Chimeras) continue to push the boundaries of targeted protein degradation in drug development. In 2025, three leading candidates—ARV-471, BMS-986365, and BGB-16673—have advanced to Phase III clinical trials, marking major milestones for this novel therapeutic class.

✨ Highlights:
✅ ARV-471 (Arvinas/Pfizer): First oral PROTAC in Phase III, targeting ER in advanced breast cancer.
✅ BMS-986365 (Bristol Myers Squibb): A powerful AR degrader showing strong efficacy in mCRPC.
✅ BGB-16673 (BeiGene): First BTK-targeting PROTAC in Phase III for relapsed/refractory CLL and other B-cell malignancies.

These programs show the potential of PROTACs to overcome drug resistance and tackle previously "undruggable" targets.

Read the full 2025 update on PROTAC drug candidates and their clinical progress 👉https://www.biochempeg.com/article/434.html

05/06/2025

🔬 Dual-Payload ADCs: The Future of Cancer Therapy
Dual-payload antibody-drug conjugates (ADCs) are reshaping oncology by combining two powerful payloads in one targeted therapy—boosting efficacy, overcoming drug resistance, and reducing toxicity.

💥 First dual-payload ADC KH815 enters clinical trials.
🧪 14 new candidates revealed at hashtag .
🚀 A game-changer in precision cancer treatment.

👉 Read more: Dual-Payload ADCs: A Revolutionary Leap in Targeted Cancer Therapy https://www.biochempeg.com/article/432.html

Learn about dual-payload ADCs: their introduction, advantages, and the latest research including KH815. Discover the challenges and future of this cancer therapy.

03/31/2025

🚀 PEG Lipids: The Key to Advanced Drug Delivery!

PEGylated lipids improve stability, circulation time, and immune response in LNP-based drugs, including mRNA vaccines, siRNA therapies, and cancer treatments. Their unique structure enhances drug efficacy, making them indispensable in modern medicine!

At Biopharma PEG, we supply high-quality PEG lipids (DSPE-PEG, DMG-PEG, etc.) to accelerate pharmaceutical innovations. Let’s shape the future of drug delivery together!

🔗 Learn more: https://www.biochempeg.com/article/429.html

02/20/2025

🌟 Exciting Growth in the Antibody-Drug Conjugate (ADC) Market! 🌟
In 2024, the ADC market continues to break records, with major drug sales showing impressive growth:
✨ Enhertu ($3.75B)
✨ Kadcyla ($2.32B)
✨ Padcev ($1.59B)
✨ Adcetris ($1.91B)
✨ Trodelvy ($1.31B, +24% from 2023)

With 17 ADC drugs approved worldwide, the industry is advancing rapidly in the fight against cancer.
🔗 Learn More: https://www.biochempeg.com/article/427.html

01/21/2025

🌟 Big news in cancer treatment! 🌟

On January 17, 2025, the U.S. FDA approved Datroway (datopotamab deruxtecan or Dato-DXd), a new antibody-drug conjugate (ADC) for adults with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have previously undergone endocrine therapy and chemotherapy.

This approval makes Datroway the 13th ADC approved by the FDA, joining an important list of groundbreaking treatments, including Kadcyla™, Adcetris™, and Enhertu™.

We’re excited about the continued progress in oncology, offering new hope to patients and their families. 🙏
https://www.biochempeg.com/article/74.html

01/16/2025

🎉 Good News!
We’re proud to share that our mPEG-pALD (20K) has officially completed its DMF filing with the U.S. FDA (DMF No. 040600)!

This is a testament to our dedication to providing premium-quality PEG derivatives that meet international standards. We’re excited to continue supporting researchers and pharmaceutical companies in their journey toward innovation and excellence.

Thank you for trusting us as your partner in drug development! 💊

👉 Learn more about our products and services at https://www.biochempeg.com/article/423.html.

01/13/2025

🎉 A Major Leap in Medical Innovation: 2024 FDA Approvals!

The FDA’s Center for Drug Evaluation and Research (CDER) has approved 50 new molecular entities (NMEs) in 2024! This includes 32 new chemical entities (NCEs) and 18 biologic entities (NBEs), marking an exciting year for the healthcare industry.

🌟 Key Stats:

Small molecules make up 91% of NCEs (31 drugs).
For biologics, 81% were antibody-based, including 10 monoclonal antibodies and 3 bispecific antibodies.
These approvals pave the way for more advanced, targeted treatments to meet patient needs across various medical conditions. 🚀


https://www.biochempeg.com/article/422.html

12/31/2024

✨ Happy New Year 2025! ✨
Thank you for being part of our journey at Biopharma PEG. We’re grateful for your support and excited to continue providing top-quality PEG solutions for your drug research and development needs.

Wishing you a year full of happiness, health, and success. Let’s make 2025 a year of remarkable progress together! 🌟